Literature DB >> 6392551

Antibodies to nonhistone nuclear antigens and antilymphocyte antibodies among children and adults with systemic lupus erythematosus and their relatives.

T J Lehman, V Hanson, N Zvaifler, G Sharp, M Alspaugh.   

Abstract

Antibodies to nonhistone nuclear antigens are found with increased frequency in the serum of patients with systemic lupus erythematosus (SLE) and their first degree relatives. We measured the prevalence of ANA and antibodies against DNA, RNP, Sm, SSA, and SSB as well as antilymphocyte antibodies (ALA) in the serum of 24 patients with childhood onset SLE and 94 of their first degree relatives and compared the prevalence of these same antibodies in 8 patients with adult onset SLE and 33 of their first degree relatives. Antibodies against DNA, RNP, and Sm occurred more frequently in the serum of adult onset SLE patients. Among the first degree relatives ALA occurred more frequently in the sera of relatives of patients with childhood onset SLE, and parental antibodies to SSA were associated with the occurrence of childhood onset SLE in 3/24 cases. Since antibodies to SSA have been shown to be related to neonatal SLE their possible relationship to childhood SLE requires further study.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6392551

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  Lupus/Sjögren's autoantibody specificities in sera with paraproteins.

Authors:  A L Sestak; J B Harley; S Yoshida; M Reichlin
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

2.  Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity.

Authors:  K K Gaither; O F Fox; H Yamagata; M J Mamula; M Reichlin; J B Harley
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

3.  Anti-Ro(SSA) autoantibodies are associated with T cell receptor beta genes in systemic lupus erythematosus patients.

Authors:  M B Frank; R McArthur; J B Harley; A Fujisaku
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.